Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.49 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.46 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12856900 | 1.00 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2DNPH1ADORA3 | |
| SCHEMBL12856879 | 0.92 | SLC29A1 (0.48) | NPC1RAB9ASMN1; SMN2DNPH1ADORA3 | |
| SCHEMBL9913214 | 0.92 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2DNPH1ADORA3 | |
| SCHEMBL13239718 | 0.86 | ABL1 (0.43) | SLC29A1 | |
| SCHEMBL12570160 | 0.86 | SLC29A1 (0.48) | ADORA3SLC29A1NT5ETSHR | |
| SCHEMBL30197028 | 0.85 | P2RY12 (0.43) | — | |
| SCHEMBL22589997 | 0.84 | P2RY1 (0.45) | ADORA3 | |
| SCHEMBL9913216 | 0.84 | SLC29A1 (0.49) | NPC1RAB9ASMN1; SMN2ADORA3SLC29A1 | |
| SCHEMBL2979765 | 0.83 | ADORA3 (0.56) | DNPH1ADORA3SLC29A1TP53TDP1 | |
| SCHEMBL1140779 | 0.81 | HIF1A (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501931-B2 | Convertible nucleoside derivatives | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2013-08-06 | — | — | US | disclosed |
| US-20100179312-A1 | CONVERTIBLE NUCLEOSIDE DERIVATIVES | LAKSHMAN MAHESH K | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179312-A1 | CONVERTIBLE NUCLEOSIDE DERIVATIVES | PNP, NUDT1, NUDT14 | NPC1 646/4885RAB9A 1292/4885SMN1; SMN2 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.